Short-selling focused research firm Marcus Aurelius Value disclosed in a new report published on its site that the firm is shorting Penumbra. In its report, the firm said it believes the “Xtra Flex debacle is symptomatic of corrosion that likely has infected most aspects of Penumbra’s business” and that “Penumbra simply cannot be trusted by investors or patients.” Further, the firm calls Penumbra to “immediately disclose a complete list of all the core labs and consultants who have been involved in every trial that Penumbra has sponsored, collaborated on, or otherwise funded since inception along with a complete list of the specific payments made to these entities since inception.”